Kestra Medical Technologies (NASDAQ:KMTS) Trading Down 6.1% – What’s Next?

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS)’s share price dropped 6.1% on Friday . The stock traded as low as $24.89 and last traded at $24.89. Approximately 49,243 shares were traded during mid-day trading, a decline of 83% from the average daily volume of 289,819 shares. The stock had previously closed at $26.52.

Analyst Ratings Changes

KMTS has been the subject of a number of recent analyst reports. Wells Fargo & Company raised their price objective on Kestra Medical Technologies from $27.00 to $28.00 and gave the stock an “overweight” rating in a research report on Friday, December 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kestra Medical Technologies in a research report on Wednesday, December 24th. BTIG Research initiated coverage on shares of Kestra Medical Technologies in a research note on Tuesday, November 18th. They issued a “buy” rating and a $32.00 price target on the stock. The Goldman Sachs Group increased their price objective on shares of Kestra Medical Technologies from $22.00 to $25.00 and gave the stock a “neutral” rating in a research report on Saturday, December 13th. Finally, Stifel Nicolaus set a $30.00 target price on Kestra Medical Technologies in a research report on Friday, December 12th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Kestra Medical Technologies has an average rating of “Moderate Buy” and an average price target of $29.14.

Kestra Medical Technologies Stock Down 4.7%

The firm’s 50-day moving average price is $26.31 and its two-hundred day moving average price is $21.44. The firm has a market cap of $1.48 billion and a PE ratio of -7.97. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.47 and a current ratio of 5.47.

Insider Activity at Kestra Medical Technologies

In other Kestra Medical Technologies news, insider Traci S. Umberger sold 10,500 shares of the company’s stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $26.69, for a total transaction of $280,245.00. Following the completion of the sale, the insider directly owned 136,633 shares of the company’s stock, valued at $3,646,734.77. This represents a 7.14% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Brian Daniel Webster sold 15,000 shares of the stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $26.59, for a total value of $398,850.00. Following the sale, the insider directly owned 409,786 shares of the company’s stock, valued at $10,896,209.74. The trade was a 3.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 3.60% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in KMTS. Quarry LP acquired a new stake in shares of Kestra Medical Technologies in the 1st quarter worth approximately $33,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Kestra Medical Technologies during the 3rd quarter worth approximately $48,000. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Kestra Medical Technologies during the 2nd quarter worth approximately $54,000. BNP Paribas Financial Markets grew its holdings in Kestra Medical Technologies by 148.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock valued at $65,000 after buying an additional 1,638 shares during the last quarter. Finally, Brown Brothers Harriman & Co. increased its position in Kestra Medical Technologies by 26.8% during the third quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock worth $74,000 after buying an additional 656 shares in the last quarter.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.